Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that China’s National Medical Products Administration (NMPA) accepted the biologics license application (BLA) for its proprietary antibody-drug conjugate (ADC) risvutatug rezetecan (HS-20093) on 24 September 2026. The application seeks approval to treat osteosarcoma patients aged 12 years and above who have failed at least two prior lines of therapy. HS-20093 targets the B7-H3 antigen and represents an innovative addition to the Group’s oncology pipeline. Chairlady Zhong Huijuan signed the voluntary disclosure on behalf of the board.